T. Rowe Price Associates’s Mersana Therapeutics MRSN Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-2,484	Closed	-$22K	–	3115
2025 Q1	$22K	Hold	2,484	–	–	﹤0.01%	3001
2024 Q4	$89K	Sell	2,484 -1,479	-37%	-$76.5K	﹤0.01%	2854
2024 Q3	$188K	Hold	3,963	–	–	﹤0.01%	2668
2024 Q2	$200K	Buy	3,963 +766	+24%	+$55.4K	﹤0.01%	2593
2024 Q1	$359K	Buy	3,197 +198	+7%	+$19.7K	﹤0.01%	2349
2023 Q4	$174K	Sell	2,999 -486	-14%	-$19.6K	﹤0.01%	2589
2023 Q3	$111K	Sell	3,485 -1,289	-27%	-$61.3K	﹤0.01%	2642
2023 Q2	$394K	Sell	4,774 -81	-2%	-$11.8K	﹤0.01%	2242
2023 Q1	$500K	Buy	4,855 +34	+0.7%	+$4.77K	﹤0.01%	2106
2022 Q4	$707K	Buy	4,821 +339	+8%	+$57.3K	﹤0.01%	1968
2022 Q3	$758K	Sell	4,482 -1,111	-20%	-$181K	﹤0.01%	1909
2022 Q2	$646K	Buy	5,593 +72	+1%	+$6.77K	﹤0.01%	2105
2022 Q1	$551K	Buy	5,521 +943	+21%	+$110K	﹤0.01%	2291
2021 Q4	$712K	Sell	4,578 -34,658	-88%	-$6.74M	﹤0.01%	2210
2021 Q3	$9.25M	Sell	39,236 -53,474	-58%	-$15.6M	﹤0.01%	1427
2021 Q2	$31.5M	Sell	92,710 -26,253	-22%	-$9.94M	﹤0.01%	1180
2021 Q1	$48.1M	Sell	118,963 -13,211	-10%	-$6.41M	﹤0.01%	1016
2020 Q4	$87.9M	Buy	132,174 +59,029	+81%	+$32.8M	0.01%	771
2020 Q3	$34M	Buy	73,145 +43,336	+145%	+$21.9M	﹤0.01%	999
2020 Q2	$17.4M	Buy	+29,809	New	+$10.2M	﹤0.01%	1180